357 related articles for article (PubMed ID: 26742637)
1. Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate.
Harrison IF; Anis HK; Dexter DT
Neurosci Lett; 2016 Feb; 614():16-23. PubMed ID: 26742637
[TBL] [Abstract][Full Text] [Related]
2. Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.
Harrison IF; Crum WR; Vernon AC; Dexter DT
Br J Pharmacol; 2015 Aug; 172(16):4200-15. PubMed ID: 26040297
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease.
Harrison IF; Powell NM; Dexter DT
J Neurochem; 2019 Jan; 148(1):136-156. PubMed ID: 30269333
[TBL] [Abstract][Full Text] [Related]
4. Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats.
Lorenc-Koci E; Lenda T; Antkiewicz-Michaluk L; Wardas J; Domin H; Smiałowska M; Konieczny J
Neurochem Int; 2011 Jun; 58(7):839-49. PubMed ID: 21419185
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats.
Inden M; Kondo J; Kitamura Y; Takata K; Nishimura K; Taniguchi T; Sawada H; Shimohama S
J Pharmacol Sci; 2005 Feb; 97(2):203-11. PubMed ID: 15684568
[TBL] [Abstract][Full Text] [Related]
6. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
7. Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Konieczny J; Czarnecka A; Kamińska K; Lenda T; Nowak P
Behav Brain Res; 2015 Apr; 283():203-14. PubMed ID: 25655509
[TBL] [Abstract][Full Text] [Related]
8. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
9. Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine.
Ferraz AC; Xavier LL; Hernandes S; Sulzbach M; Viola GG; Anselmo-Franci JA; Achaval M; Da Cunha C
Brain Res; 2003 Oct; 986(1-2):200-5. PubMed ID: 12965246
[TBL] [Abstract][Full Text] [Related]
10. Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system x
Bentea E; Van Liefferinge J; Verbruggen L; Martens K; Kobayashi S; Deneyer L; Demuyser T; Albertini G; Maes K; Sato H; Smolders I; Lewerenz J; Massie A
Exp Neurol; 2017 Apr; 290():15-28. PubMed ID: 28024798
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.
Vernon AC; Johansson SM; Modo MM
BMC Neurosci; 2010 Jan; 11():1. PubMed ID: 20051106
[TBL] [Abstract][Full Text] [Related]
13. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
14. Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease.
Konieczny J; Jantas D; Lenda T; Domin H; Czarnecka A; Kuter K; Śmiałowska M; Lasoń W; Lorenc-Koci E
Neurotox Res; 2014 Oct; 26(3):255-73. PubMed ID: 24842651
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of ATP production ameliorates motor and cognitive impairments in a mouse model of MPTP-induced Parkinson's disease.
Haga H; Matsuo K; Yabuki Y; Zhang C; Han F; Fukunaga K
Neurochem Int; 2019 Oct; 129():104492. PubMed ID: 31229554
[TBL] [Abstract][Full Text] [Related]
16. Selective increase of in vivo firing frequencies in DA SN neurons after proteasome inhibition in the ventral midbrain.
Subramaniam M; Kern B; Vogel S; Klose V; Schneider G; Roeper J
Eur J Neurosci; 2014 Sep; 40(6):2898-909. PubMed ID: 25059097
[TBL] [Abstract][Full Text] [Related]
17. Pedunculopontine cell loss and protein aggregation direct microglia activation in parkinsonian rats.
Elson JL; Yates A; Pienaar IS
Brain Struct Funct; 2016 May; 221(4):2319-41. PubMed ID: 25989851
[TBL] [Abstract][Full Text] [Related]
18. Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease.
Fletcher EJR; Moon LDF; Duty S
BMC Neurosci; 2019 Dec; 20(1):61. PubMed ID: 31862005
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration.
Zhang X; Xie W; Qu S; Pan T; Wang X; Le W
Biochem Biophys Res Commun; 2005 Jul; 333(2):544-9. PubMed ID: 15950935
[TBL] [Abstract][Full Text] [Related]
20. Nifedipine and nimodipine protect dopaminergic substantia nigra neurons against axotomy-induced cell death in rat vibrosections via modulating inflammatory responses.
Daschil N; Humpel C
Brain Res; 2014 Sep; 1581():1-11. PubMed ID: 25038562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]